Graphite Bio, Inc.
Formerly Longbow Therapeutics Inc.
Graphite Bio, Inc. is listed today as LENZ Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2021 | $151 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company LENZ Therapeutics, Inc., its revenue in fiscal 2025 came from these product and service lines: License revenue $17.50 million (92%).
Annual report (SEC XBRL) · Dec 2025
Graphite Bio, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2021).
SEC Form D · Mar 2021
The industry group it chose in its notices: Biotechnology.
SEC Form D · Mar 2021
Products and services#
No products or services of Graphite Bio, Inc. are on record.
Investors#
13 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| 436, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Joseph Jimenez | Person | not stated | not stated | Held Series B preferred stock, director (Form 3, 2021) | SEC Form 3 |
| Joshua Lehrer-Graiwer | Person | not stated | not stated | Held Series B preferred stock, director (Form 3, 2021) | SEC Form 3 |
| Katherine V. Stultz | Person | not stated | not stated | Held Series B preferred stock (Form 3, 2021) | SEC Form 3 |
| Perry A. Karsen | Person | not stated | not stated | Held Series B preferred stock, director (Form 3, 2021) | SEC Form 3 |
| Phil Gutry | Person | not stated | not stated | Held Series B preferred stock (Form 3, 2021) | SEC Form 3 |
| Samsara BioCapital, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Versant Vantage II GP-GP, LLC | Other | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Versant Vantage II GP, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Versant Vantage II, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Versant Venture Capital VI, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Versant Ventures VI GP-GP, LLC | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Versant Ventures VI GP, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 35 investors.
Largest shareholders today
Institutions holding LENZ Therapeutics, Inc. shares, as of Sep 30, 2026.
- Ra Capital Management, L.P.$16 M13.30%
- Alpha Wave Global, LP$14 M11.50%
- BlackRock, Inc.$13 M10.94%
- Versant Venture Management, LLC$10 M8.46%
- Millennium Management LLC$4 M3.69%
- Vanguard Capital Management LLC$4 M3.49%
- 72 Investment Holdings, LLC$4 M3.24%
- Squarepoint Ops LLC$4 M3.08%
- Blue Owl Capital Holdings LP$3 M2.49%
- Two Sigma Investments, LP$3 M2.27%
- C WorldWide Group Holding A/S$3 M2.23%
- Trexquant Investment LP$2 M1.99%
- FMR LLC$2 M1.95%
- Primecap Management Co/ca/$2 M1.50%
- Tang Capital Management LLC$2 M1.44%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Josh Lehrer | Executive officer | Mar 2021 |
| Katherine Stultz | Executive officer | Mar 2021 |
| Philip Gutry | Executive officer | Mar 2021 |
| Abraham Bassan | Director | Mar 2021 |
| Carlo Rizzuto | Director | Mar 2021 |
| Jerel Davis | Director | Mar 2021 |
| Joe Jimenez | Director | Mar 2021 |
| Josh Lehrer | Director | Mar 2021 |
| Maria Grazia Roncarolo | Director | Mar 2021 |
| Matthew Porteus | Director | Mar 2021 |
| Perry Karsen | Director | Mar 2021 |
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.